Targeting cardiometabolic reprogramming provides a theoretical foundation for developing right ventricular-directed therapies to complement existing pulmonary arterial hypertension treatments.
Targeting cardiometabolic reprogramming offers a potential novel therapeutic strategy for right ventricular dysfunction in pulmonary arterial hypertension.
With the understanding on right ventricular (RV) dysfunction in pulmonary arterial hypertension (PAH), the perspective innovatively integrates research paradigms on targeting cardiometabolic reprogramming of RV protective therapies to break through the bottleneck of current PAH treatment. The research focuses on three core areas: analyzing and validating metabolic dysregulation in the RV of PAH, exploring cell-specific metabolic dysregulation in the heart of PAH, and probing into the therapeutic strategy for PAH targeting RV metabolism. These aspects aim to deepen the scientific understanding of cardiometabolic reprogramming of RV dysfunction in PAH. This work provides a theoretical foundation and experimental evidence for developing RV-directed therapies that complement existing PAH treatments and improve patient outcomes.
Liu et al. (Fri,) conducted a review in Pulmonary arterial hypertension. RV-directed therapies targeting cardiometabolic reprogramming was evaluated. Targeting cardiometabolic reprogramming provides a theoretical foundation for developing right ventricular-directed therapies to complement existing pulmonary arterial hypertension treatments.